Company intelligence / Profile preview

Cytomos

Ownership: Private
Employees: ~26
Development stage: Preclinical

Overview

Cytomos has commercialized its first benchtop analyzer product Celledonia™, built on the AuraCyt™ platform. The technology enables real-time, label-free single-cell analytics to accelerate drug discovery and biomanufacturing by providing earlier insights into cellular physiology. Early market traction includes trials with global partners and interest from top pharma companies. No clinical trial results are reported as the company is a tools/platform provider rather than a therapeutics developer.

Therapeutic areas: Other
Modalities: Not directly therapeutic; provides enabling technology for cell analysis, applicable to biologics, cell and gene therapies, and advanced therapy medicinal products (ATMPs)
Industry: Non-Drug Biotech

Partnerships

Trials planned with global partners including high-profile technology developers and at least one top 10 pharma company; ongoing collaborations in bioprocessing/ATMP space

Beyond the preview

Go deeper on Cytomos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytomos.

Explore the full profile